Physicians' Academy for Cardiovascular Education

Lipids

Healthy lifestyle interventions for CVD risk reduction in secondary prevention

3' education - Sep. 25, 2023 - Ruxandra Maria Christodorescu, MD and Nadia Bonekamp, MD

Challenges in ASCVD reduction and TG-related risk

10' education - Sep. 20, 2023 - Erik Stroes, MD, PhD

Unmet needs in lowering LDL-c

10' education - Sep. 14, 2023 - Stephen Nicholls, MD, PhD

The evolving need and challenges to reach LDL-c targets in high-risk patients

10' education - Sep. 14, 2023 - Kausik Ray, MD

In which patients is treatment with icosapent ethyl most beneficial?

3' education - Sep. 12, 2023 - Pascal Burger, MD

Combined ESC guidelines for the entire ACS spectrum

3' education - Sep. 11, 2023 - Borja Ibáñez, MD, PhD

Large study assessing long-term efficacy and safety of PCSK9 siRNA

3' education - Sep. 4, 2023 - R. Scott Wright, MD

No increase of glucose levels with bempedoic acid

3' education - Sep. 4, 2023 - Kausik Ray, MD

Ongoing benefit with bempedoic acid in reducing total incidence of MACE

3' education - Aug. 27, 2023 - Stephen Nicholls, MD

Debate: Are diet and nutrition important for LDL-c lowering? - part 2

3' education - June 27, 2023 - Ulrich Laufs, MD, PhD

Debate: Are diet and nutrition important for LDL-c lowering? - part 1

3' education - June 27, 2023 - Maciej Banach, MD, PhD

Updates on management of lipids beyond LDL-c and (new-onset) diabetes in preventive cardiology

3' education - June 8, 2023 - Maciej Banach, MD, PhD

Integrating icosapent ethyl in preventive strategies: Practical guidance

10' education - June 6, 2023 - Victor Aboyans, MD, PhD

The benefits of icosapent ethyl in addressing residual risk: What is the evidence?

10' education - May 26, 2023 - Lale Tokgözoğlu, MD

Causes of coronary thrombosis

3' education - May 25, 2023 - Renu Virmani, MD

How to manage patients with elevated Lp(a)

3' education - May 23, 2023 - Florian Kronenberg, MD, PhD

Innovations in lipid therapy

3' education - May 22, 2023 - Peter Libby, MD

Reassessing the role of triglycerides in residual cardiovascular risk

10' education - May 16, 2023 - Richard Hobbs, MD

4-year follow-up data on efficacy and safety of PCSK9 siRNA

5' education - May 8, 2023 - Kausik Ray, MD

Imaging study with PCSK9 inhibitor in patients with stable CAD

5' education - Apr. 17, 2023 - Annapoorna Kini, MD

ILEP recommendations on use of bempedoic acid

10' education - Mar. 30, 2023 - Maciej Banach, MD, PhD

Do personalized reminders to clinicians result in higher use of high-intensity statins?

3' education - Mar. 23, 2023 - Prof. Salim Virani, MD, PhD

Initiating PCSK9 mAb after ACS: When and how to start?

10' education - Mar. 22, 2023 - Prof. Wouter Jukema, MD, PhD and Prof. Pasquale Perrone-Filardi, MD, PhD

Interesting developments in the field of PCSK9 inhibition

3' education - Mar. 21, 2023 - Prof. Deepak Bhatt, MD

Promising results for oral PCSK9i to proceed to phase 3 trials

3' education - Mar. 8, 2023 - Prof. Christie Ballantyne, MD

Residual inflammatory risk is major driver of CV events and mortality in statin-treated patients

3' education - Mar. 7, 2023 - Prof. Paul Ridker, MD

New evidence-based non-statin treatment to lower LDL-c and CV risk

3' education - Mar. 6, 2023 - Prof. Peter Libby, MD

Assocation between low-carbohydrate high-fat diet and MACE

3' education - Mar. 6, 2023 - Liam Brunham, MD, PhD

Where is bempedoic acid going to fit in?

3' education - Mar. 6, 2023 - Prof. Kausik Ray, MD

Strengths and limitations of phase 3 trial with bempedoic acid

3' education - Mar. 5, 2023 - Prof. Eugene Yang, MD

More evidence for association between higher Lp(a) levels and calcific aortic valve disease

Literature - Sep. 25, 2023 - Pantelidis P, et al. - Cardiovasc Res. 2023

A systematic review and meta-analysis showed higher Lp(a) levels were associated with the onset, progression, and serious adverse outcomes of calcific aortic valve disease, particularly in younger individuals and male-dominant populations.

Healthy lifestyle interventions for CVD risk reduction in secondary prevention

3' education - Sep. 25, 2023 - Ruxandra Maria Christodorescu, MD and Nadia Bonekamp, MD
**ESC Congress 2023** How do healthy lifestyle interventions fit in the current therapeutic landscape for patients with established CVD? Nadia Bonekamp interviews Ruxandra Maria Christodorescu about this topic.

ESC Congress 2023 How do healthy lifestyle interventions fit in the current therapeutic landscape for patients with established CVD? Nadia Bonekamp interviews Ruxandra Maria Christodorescu about this topic.

Challenges in ASCVD reduction and TG-related risk

10' education - Sep. 20, 2023 - Erik Stroes, MD, PhD

"What is hypertriglyceridemia? We have to think particles", says Erik Stroes. In this video, he explains the relationship between triglyceride-risk lipoproteins and atherogenic risk.

Higher circulating levels of EPA, but not DHA, associated with lower MACE risk

Literature - Sep. 18, 2023 - Le VT, et al - Front Cardiovasc Med. 2023

In an observational cohort study, higher plasma levels of eicosapentaenoic acid (EPA), but not docosahexaenoic acid (DHA), were associated with a lower 10-year risk of MACE. Adjustment for DHA level increased the protective effect of higher EPA levels.

Angiographic stenosis regression with PCSK9 inhibitor in acute MI

Literature - Sep. 14, 2023 - Bär S, et al. - EuroIntervention. 2023

A prespecified substudy of the PACMAN-AMI trial showed 1 year of alirocumab, on top of rosuvastatin, resulted in regression of the angiographic diameter stenosis of non-obstructive coronary lesions in acute MI patients, compared with an increase with placebo.

Unmet needs in lowering LDL-c

10' education - Sep. 14, 2023 - Stephen Nicholls, MD, PhD
Despite the use of statins for LDL-c lowering, there remains a residual risk in patients with high CV risk. Stephen Nicholls talks about recommendations in guidelines and real world clinical practice.

Despite the use of statins for LDL-c lowering, there remains a residual risk in patients with high CV risk. Stephen Nicholls talks about recommendations in guidelines and real world clinical practice.

The evolving need and challenges to reach LDL-c targets in high-risk patients

10' education - Sep. 14, 2023 - Kausik Ray, MD
According to the latest registries, the majority of high- and very high-risk patients do not accieve 2019 ESC/EAS recommended LDL-c goals. Kausik Ray discusses how LDL-c goal attainment can be improved.

According to the latest registries, the majority of high- and very high-risk patients do not accieve 2019 ESC/EAS recommended LDL-c goals. Kausik Ray discusses how LDL-c goal attainment can be improved.

In which patients is treatment with icosapent ethyl most beneficial?

3' education - Sep. 12, 2023 - Pascal Burger, MD
**ESC Congress 2023** Pascal Burger presents the results of a subanalysis of the REDUCE-IT trial, which examined the treatment effects of icosapent ethyl in subgroups with different 5-year residual CV risks.

ESC Congress 2023 Pascal Burger presents the results of a subanalysis of the REDUCE-IT trial, which examined the treatment effects of icosapent ethyl in subgroups with different 5-year residual CV risks.

Combined ESC guidelines for the entire ACS spectrum

3' education - Sep. 11, 2023 - Borja Ibáñez, MD, PhD
The ESC guidelines for NSTE-ACS and STEMI have been combined in one document, as different presentations of ACS are all part of one spectrum, explains Borja Ibáñez. He discusses the highlights of the new guidelines on the management of ACS.

ESC Congress 2023 The ESC guidelines for NSTE-ACS and STEMI have been combined in one document, as different presentations of ACS are all part of one spectrum, explains Borja Ibáñez. He discusses the highlights of the new guidelines on the management of ACS.

Oral Lp(a) inhibitor shows promise in phase 1 trial

News - Sep. 5, 2023

ESC Congress 2023 In a phase 1 trial, daily administration of the oral small molecule muvalaplin for 14 days lowered Lp(a) levels up to 65%, with no safety or tolerability concerns.

Small PCSK9 binding protein reduces LDL-c and is safe in patients with HeFH

News - Sep. 5, 2023

ESC Congress 2023 Investigators of the phase 3 LIBerate-HeFH trial reported data on the efficacy and safety of the small PCSK9 binding protein lerodalcibep in patients with heterozygous FH (HeFH).

Long-term efficacy and safety data of PCSK9 siRNA in patients with high CV risk and elevated LDL-c

News - Sep. 4, 2023

ESC Congress 2023 The ORION-8 trial, an open-label extension of ORION-3/9/10/11, demonstrated the efficacy, safety and tolerability of inclisiran in patients with high cardiovascular risk and elevated LDL-c.